Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
Open Access
- 5 February 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 28, 264-276
Abstract
No abstract availableKeywords
Funding Information
- Magnus Ehrnroothin Säätiö (4706235)
- Syöpäjärjestöt (4706116)
- Helsingin Yliopisto
- European Research Council
- Jane ja Aatos Erkon Säätiö (4705796, 797011004)
- Research Council of Finland
This publication has 28 references indexed in Scilit:
- Immune evasion in cancer: Mechanistic basis and therapeutic strategiesSeminars in Cancer Biology, 2015
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector FunctionsChemistry & Biology, 2014
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanomaJournal of Experimental Medicine, 2013
- Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced MelanomaClinical Cancer Research, 2013
- Modulation of antibody effector functionExperimental Cell Research, 2011
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsmAbs, 2010
- Cancer incidence and risk factors after solid organ transplantationInternational Journal of Cancer, 2009
- Androgen Receptor Attenuation of Ad5 Replication: Implications for the Development of Conditionally Replication Competent AdenovirusesMolecular Therapy, 2007
- Restricted replication of human adenovirus type 5 in mouse cell linesVirus Research, 1989
- The half-lives of serum immunoglobulins in adult miceEuropean Journal of Immunology, 1988